27
Feb

Israeli-American biotech Chiasma has raised $70 million in Series E cash, moving on from an aborted collaboration with Roche and rolling toward FDA approval with a treatment for the hormone disorder acromegaly.

…read more

Source: Chiasma hauls in $70M to write its post-Roche future

    

0 No comments